Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Posts Fallen Q3 Revenues, Widened Net Loss

SAN FRANCISCO, Nov. 7 - Exelixis today reported decreased revenue for the third quarter of 2002.


The company said its total revenue was $10.4 million in the third quarter which ended September 30, compared to $11.9 million in the same quarter of 2001.


Exelixis reported a net loss based on generally accepted accounting principles of $22.9 million, or $.41 per share, in the third quarter 2002 compared to a net loss of $16.5 million, or $.35 per share, in the year-ago period.


R&D spending increased to $28.5 million, excluding stock compensation expense of $400,000, compared to $21.3 million, excluding stock compensation of $1.1 million, in the same period a year ago.


Exelixis also reported $159.1 million in cash, cash equivalents, and short-term investments at the end of September 2002.


Click here for more information.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.